Dr. Karl Naegler joined Wellington as a Managing Partner on January 1, 2020. Karl brings to Wellington a strong track record of investments in early and later stage life science companies as well as deep sector knowledge and an extensive global network from over 18 years of industry experience.
8. January 2020
Wellington Partners today announced the final close of its fifth-generation fund Wellington Partners Life Science Fund V (WPLS-V). The fund closed at EUR 210 million, making it the largest life science dedicated fund raised by Wellington Partners to date. WPLS-V will build a portfolio of approximately 15-20 companies, ranging in focus from novel biotechnology platforms, new therapeutics and medical devices, including selected investments in diagnostics and digital medicine. All of the fund’s investments will target substantial improvements to current medical practice for the benefit of patients, practitioners, and payors alike.
by eazee-designstudio
RIG-GING AN EXIT: Rigontec takeout gives Wellington quick exit, momentum into new Fund.
